CVS Health Co. (NYSE:CVS) is Poplar Forest Capital LLC’s 9th Largest Position

Poplar Forest Capital LLC decreased its position in CVS Health Co. (NYSE:CVSGet Rating) by 18.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 362,305 shares of the pharmacy operator’s stock after selling 84,353 shares during the period. CVS Health comprises approximately 3.8% of Poplar Forest Capital LLC’s portfolio, making the stock its 9th biggest holding. Poplar Forest Capital LLC’s holdings in CVS Health were worth $36,669,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Macroview Investment Management LLC boosted its stake in CVS Health by 128.3% in the 1st quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock worth $25,000 after buying an additional 136 shares during the last quarter. West Bancorporation Inc. purchased a new position in shares of CVS Health in the 4th quarter worth about $25,000. Claremont Financial Group Inc. purchased a new position in shares of CVS Health in the 4th quarter worth about $26,000. Stuart Chaussee & Associates Inc. raised its holdings in shares of CVS Health by 123.0% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 171 shares during the period. Finally, Capital Advisors Ltd. LLC raised its holdings in shares of CVS Health by 125.7% in the 4th quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock worth $33,000 after purchasing an additional 176 shares during the period. Institutional investors and hedge funds own 78.00% of the company’s stock.

Insider Buying and Selling at CVS Health

In other news, EVP Thomas M. Moriarty sold 138,654 shares of the business’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $95.00, for a total value of $13,172,130.00. Following the sale, the executive vice president now owns 626,273 shares of the company’s stock, valued at approximately $59,495,935. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is owned by company insiders.

CVS Health Stock Performance

CVS Health stock traded up $0.32 during mid-day trading on Friday, hitting $102.19. 229,203 shares of the company’s stock traded hands, compared to its average volume of 4,881,003. The firm has a 50 day moving average price of $94.28 and a 200 day moving average price of $99.95. The company has a quick ratio of 0.62, a current ratio of 0.91 and a debt-to-equity ratio of 0.67. The company has a market cap of $134.00 billion, a PE ratio of 16.56, a price-to-earnings-growth ratio of 1.55 and a beta of 0.75. CVS Health Co. has a one year low of $79.33 and a one year high of $111.25.

CVS Health (NYSE:CVSGet Rating) last announced its earnings results on Wednesday, August 3rd. The pharmacy operator reported $2.40 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.24. The firm had revenue of $80.64 billion for the quarter, compared to the consensus estimate of $76.38 billion. CVS Health had a return on equity of 15.19% and a net margin of 2.65%. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.42 EPS. On average, equities analysts forecast that CVS Health Co. will post 8.57 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 22nd were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.15%. The ex-dividend date of this dividend was Thursday, July 21st. CVS Health’s payout ratio is currently 35.77%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. UBS Group raised their price objective on CVS Health from $118.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday. Tigress Financial raised their target price on CVS Health from $122.00 to $125.00 in a report on Thursday, April 7th. Deutsche Bank Aktiengesellschaft raised their target price on CVS Health from $113.00 to $120.00 in a report on Thursday. Loop Capital began coverage on CVS Health in a research note on Thursday, June 16th. They set a “buy” rating and a $120.00 price objective for the company. Finally, Sanford C. Bernstein lowered CVS Health from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $122.00 to $112.00 in a research note on Thursday, May 26th. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $116.90.

About CVS Health

(Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Further Reading

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.